NAD+ — PeptideReport.ai

A Note on Category

Not a Peptide — Why It's Covered Here Anyway

NAD+ is a dinucleotide coenzyme — chemically unrelated to the amino-acid-chain peptides that make up most of this site's compound library. It earns a profile here for the same reason it appears constantly in longevity marketing and in patient questions: it is sold and discussed in the same wellness-clinic and peptide-adjacent commerce channels as BPC-157, Epithalon, and other compounds on this site, and patients frequently ask about it in the same conversation. This profile applies the same evidence-first standard used everywhere else on PeptideReport.ai, which in this case means being direct about how thin the human evidence actually is relative to the marketing claims surrounding it.

Mechanism

Why NAD+ Matters Biochemically

NAD+ is not a hypothesis — its biochemical role is textbook cell biology. Whether raising its levels exogenously produces the clinical benefits attributed to it in wellness marketing is the actual open question.

Redox Cofactor

Electron carrier in mitochondrial ATP production

NAD+/NADH cycling is central to glycolysis, the TCA cycle, and oxidative phosphorylation. Cellular NAD+ levels decline with age in multiple tissues in animal models, which is the biological rationale invoked for supplementation — though declining levels correlating with age is not the same as proving that restoring them reverses age-related dysfunction in humans.

Sirtuin Substrate

Required cofactor for SIRT1-7 deacetylase activity

Sirtuins regulate DNA repair, mitochondrial biogenesis, and metabolic gene expression, and require NAD+ as a substrate. This is the core mechanistic link cited in "NAD+ for longevity" claims — but sirtuin activation as a translatable human longevity intervention remains unproven, and the sirtuin-activator drug field (resveratrol and related compounds) has a long history of promising preclinical data that did not translate cleanly to human outcomes.

PARP Substrate

Consumed by PARP enzymes during DNA damage repair

PARP1 activation after DNA damage consumes large amounts of NAD+, and chronic DNA damage (as seen with aging) is proposed to compete with sirtuins for a shared, limited NAD+ pool — a mechanistically plausible but still largely preclinical model for age-related NAD+ decline.

Human Evidence — Level V / Preliminary

What Human Data Actually Exists

This is the most important section on this page. The human evidence for IV NAD+ specifically — as opposed to its oral precursors NMN and NR, which have a somewhat larger (though still modest) RCT literature — is limited to small, largely uncontrolled pilot and retrospective studies.

Retrospective IV NAD+ vs. IV NR Tolerability Pilot (2026)

n = 14 (6 NAD+, 8 NR) · retrospective chart review, commercial wellness clinic

DesignRetrospective, no placebo arm, no randomization

NAD+ tolerabilityModerate-severe GI symptoms, tachycardia, chest pressure during infusion

Comparator (NR)Mild symptoms only, 60% shorter infusion time

Efficacy findingsAuthors explicitly labeled metabolic marker changes "exploratory"; no efficacy claim supported

The authors' own stated limitation: "absence of a placebo-controlled arm limits the generalizability and interpretation of the metabolic biomarker data." This is the most direct human data specifically on IV NAD+ available as of this writing.

Oral NMN/NR RCT Literature (broader, indirect)

Multiple small RCTs, healthy and overweight/older adults

What's shownReliable, dose-dependent increase in blood NAD+ metabolite levels

What's NOT shownConsistent, clinically meaningful improvement in hard outcomes (mortality, cognitive decline, frailty)

Raising NAD+ levels is well established for oral precursors; translating that into a measurable clinical benefit is the unresolved step, and this data does not transfer directly to IV NAD+ itself, which uses a different route and delivers the intact dinucleotide rather than a precursor.

Reading the Marketing Against the Data

IV NAD+ is marketed heavily for energy, cognitive clarity, addiction recovery, and anti-aging, often alongside dramatic before/after patient testimonials. None of these specific claims are supported by a completed, placebo-controlled human RCT of IV NAD+ as of this writing. Patients considering IV NAD+ should understand they are purchasing an unregulated wellness-clinic infusion with a genuinely poor tolerability profile in the one pilot study specifically examining it, not an evidence-backed medical treatment.

Regulatory Status & Available Forms

Three Very Different Regulatory Categories

"NAD+" is used loosely to describe three distinct product categories with different regulatory status, different evidence bases, and different administration routes. Conflating them is one of the most common sources of confusion in wellness marketing.

IV NAD+ (Intact Dinucleotide)

Unregulated infusion

Administered at wellness clinics and some compounding pharmacies; not FDA-approved as a drug for any indication; the tolerability data above is specific to this form

Nicotinamide Riboside (NR)

Lawful dietary supplement

Oral precursor; sold over the counter; better-tolerated than IV NAD+ in the pilot comparison above

Nicotinamide Mononucleotide (NMN)

Lawful dietary supplement (as of 2025 FDA reversal)

Oral precursor; the FDA had previously excluded NMN from the dietary supplement definition due to prior investigational new drug (IND) authorization, then reversed that position following industry litigation

Because none of these three forms is an FDA-approved drug, PeptideReport.ai does not publish a self-administration dosing guide for any of them. The oral supplement forms carry lower acute risk than IV administration per the pilot data above, but "lower risk" is not the same as "proven benefit," and neither form has cleared a confirmatory human efficacy trial.

Clinical Decision Tool

Candidate Framework

Reasonable Context

Lower-Risk Exploration

✓Interest in oral NMN/NR as a lawful, low-acute-risk supplement, with expectations calibrated to the modest evidence base

✓Discussing NAD+-pathway biology as a research interest area, distinct from purchasing an IV infusion

Poor Fit

Reconsider

⚠Anyone with cardiac history considering IV NAD+, given the tachycardia/chest-pressure signal in the only tolerability study specifically examining it

⚠Anyone expecting IV NAD+ to treat addiction, reverse cognitive decline, or meaningfully slow aging based on current evidence

⚠Anyone choosing a costly IV infusion over a well-studied FDA-approved intervention for the same underlying goal (e.g., metabolic health, cognitive support)

Path to Level I Evidence

What's Actually Missing

A placebo-controlled, adequately powered RCT of IV NAD+ specifically — not its oral precursors — measuring predefined clinical endpoints (not just blood biomarkers) over a meaningful follow-up period, has not been completed. Until one is, IV NAD+ remains a Level V (preliminary/preclinical-adjacent) intervention regardless of how it is marketed, and PeptideReport.ai will continue to describe it that way.

Common Questions

Frequently Asked Questions

Is NAD+ a peptide?

No. NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme, not a peptide — it isn't built from a chain of amino acids the way BPC-157, Epithalon, and other compounds on this site are. It's covered here because it's marketed and sold through the same wellness-clinic and peptide-adjacent channels, and patients frequently ask about it in the same conversation as genuine peptides.

Does IV NAD+ therapy actually work — what does the research show?

The honest answer is that no completed, placebo-controlled human trial has demonstrated that IV NAD+ delivers the energy, cognitive, anti-aging, or addiction-recovery benefits attributed to it in marketing. The most direct human data available — a small 2026 retrospective pilot comparing IV NAD+ to IV NR in 14 patients — had no placebo arm, and its authors explicitly labeled the metabolic marker changes "exploratory," not evidence of efficacy.

Is NAD+ IV therapy FDA-approved or regulated?

No. IV NAD+ is not FDA-approved as a drug for any indication, and infusions given at wellness clinics are an unregulated wellness-clinic offering rather than an approved medical treatment. Its oral precursors, NMN and NR, are regulated only as dietary supplements, not as drugs.

What's the difference between NAD+ IV, NMN, and NR?

IV NAD+ infuses the intact dinucleotide directly into the bloodstream and is not a regulated drug product; NMN and nicotinamide riboside (NR) are oral precursor supplements that the body converts into NAD+, and both are lawful dietary supplements — NMN only since a 2025 FDA reversal of its earlier exclusion. The oral precursor RCT literature reliably shows increased blood NAD+ metabolites, but that data does not transfer directly to the IV form, which uses a different route and delivers a different molecule.

What are the risks or side effects of IV NAD+?

In the one retrospective pilot specifically examining IV NAD+ tolerability, patients experienced moderate-to-severe GI symptoms, tachycardia, and chest pressure during infusion — a meaningfully worse tolerability profile than IV NR in the same comparison. Anyone with a cardiac history should discuss this signal with a physician before considering an infusion; this page does not provide dosing or infusion-protocol guidance.

Is NAD+ therapy worth the cost given the current evidence?

Based on the evidence available as of this writing, IV NAD+ is a costly, unregulated infusion with a poor tolerability signal in the only pilot study to examine it directly, and no completed placebo-controlled trial supporting its marketed benefits. Patients weighing the cost should recognize they are purchasing an unproven wellness service, not an evidence-backed medical treatment, and should discuss any interest in NAD+-pathway support with a licensed physician.

Physician Author

Dr. Scott DelBoccio, DMD

Founding Author · PeptideReport.ai

Dr. Scott DelBoccio, DMD is a retired dentist with thirty years of clinical practice — including a hormone-therapy and regenerative wellness practice built around individual bloodwork, national lecturing on advanced dental and surgical techniques, mentoring new dentists on practice management, and innovating dental and laser procedures now used throughout North America — who is now heavily involved in peptide research and development, building beginner-to-advanced optimization frameworks calibrated to the individual, and holds workshops and lectures on peptide therapeutics for other clinicians and researchers. PeptideReport.ai was founded on the principle that E-E-A-T-compliant, physician-authored content should say plainly when an intervention's evidence base does not match its marketing — NAD+ is one of the clearest examples of that gap in the current wellness landscape. Disclosed conflict of interest: Dr. DelBoccio's own supplement brand, Elyva, includes NAD+ in its formulation — see the full disclosure on the About page.